OTC: NONOF - Novo Nordisk A/S

Yield per half year: -47.27%
Dividend yield: +1.80%
Sector: Healthcare

Share chart Novo Nordisk A/S

Extended chart Simple chart
Financial Markets by TradingView

About Novo Nordisk A/S

Novo Nordisk A/S, медицинская компания, занимается исследованиями, разработками, производством и маркетингом фармацевтической продукции по всему миру. Он работает в двух сегментах: уход за диабетом и ожирением и редкие заболевания. Сегмент лечения диабета и ожирения предоставляет продукты в области инсулинов, GLP-1 и родственных систем доставки, пероральных противодиабетических продуктов, ожирения, глюкагона, игл и других хронических заболеваний.

more details
Сегмент редких заболеваний предлагает продукты для лечения гемофилии, заболеваний крови, эндокринных заболеваний, нарушений роста и заместительной гормональной терапии. Компания заключила соглашения о сотрудничестве с Gilead Sciences, Inc. Компания была основана в 1923 году и имеет штаб-квартиру в Багсверде, Дания.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета dkk
Див.доход ао 2.56
Дивиденд ао 1.14
Сайт https://www.novonordisk.com
Цена ао 71.49
Change price per day: 0% (64.44)
Change price per week: +2.06% (63.14)
Change price per month: -14.78% (75.62)
Change price per 3 month: -23.06% (83.75)
Change price per half year: -47.27% (122.2)
Change price per year: -48.04% (124.02)
Change price per 3 year: -47.42% (122.56)
Change price per 5 year: +22.45% (52.625)
Change price per year to date: -23.96% (84.748)
All parameters

Underestimation

Title Value Grade
P/S 9.47 1
P/BV 19.17 1
P/E 27.24 6
EV/EBITDA 19.18 6
Total: 5.63

Efficiency

Title Value Grade
ROA, % 25.89 8
ROE, % 80.78 10
Total: 7.83

Dividends

Title Value Grade
Div yield, % 1.8 4.5
DSI 0.7857 7.86
Total: 3.22

Debt

Title Value Grade
Debt/EBITDA 0.6948 9
Total: 8.4

Growth impulse

Title Value Grade
Yield Revenue, % 128.76 10
Yield Ebitda, % 145.68 10
Yield EPS, % 25.71 4
Total: 8.8
More

Institutions Volume Share, %
Boston Common Asset Management, LLC 366124 0.01
Kennedy Capital Management, Inc. 40184 0
Zevin Asset Management, Inc. 32880 0
Atlas Capital Advisors LLC 5218 0
Gamma Investing LLC 258 0



Head Job title Payment Year of birth
Mr. Lars Fruergaard Jorgensen President, CEO & Member of Management Board 4.67M 1966 (59 years)
Mr. Karsten Munk Knudsen Executive VP, CFO & Member of the Management Board 1.85M 1971 (54 years)
Mr. Henrik Ehlers Wulff Executive VP of Product Supply, Quality & IT and Member of the Management Board 1.87M 1970 (55 years)
Ms. Camilla Sylvest Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board 1.82M 1972 (53 years)
Dr. Martin Holst Lange Executive VP of Development & Member of the Management Board 1.76M 1970 (55 years)
Dr. Marcus Schindler Ph.D. EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board 1.76M 1966 (59 years)
Mr. Maziar Mike Doustdar Executive VP of International Operations & Member of the Management Board N/A 1970 (55 years)
Mr. Douglas J. Langa Executive VP of North America Operations & Member of Management Board N/A 1966 (59 years)
Mr. Ludovic Helfgott Executive VP, Head of Rare Disease & Member of Management Board N/A 1974 (51 year)
Ms. Tania Sabroe Executive VP of Global People & Organisation and Member of Management Board N/A 1977 (48 years)

Address: Denmark, Bagsvaerd, Novo Alle 1 - open in Google maps, open in Yandex maps
Website: https://www.novonordisk.com